Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | RXRA | P19793 | 3/20 | 0.46 |
| ▸ | RXRG | P48443 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11653596 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB | |
| SCHEMBL6891790 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB | |
| SCHEMBL6891449 | 0.84 | POLB (0.50) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB | |
| SCHEMBL6890990 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB | |
| SCHEMBL6892407 | 0.82 | MAPT (0.49) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB | |
| SCHEMBL9719992 | 0.81 | ALOX15 (0.59) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB | |
| SCHEMBL6890994 | 0.79 | POLB (0.54) | SMN1; SMN2ALOX15TSHRHSD17B10NPC1 | |
| SCHEMBL8884260 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB | |
| SCHEMBL875632 | 0.76 | ALOX15 (0.57) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB | |
| SCHEMBL7336195 | 0.76 | PPARG (0.53) | SMN1; SMN2ALOX15TSHRHSD17B10RXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230303611-A1 | SYNTHESIS OF AN ANTIVIRAL AZASUGAR TRIPHOSPHATE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-09-28 | — | — | US | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-109862903-B | Therapeutic SALL4 peptides | 新加坡国立大学 | 2023-04-14 | — | — | CN | disclosed |
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| CN-113967258-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-25 | — | — | CN | disclosed |
| CN-113956325-A | FAP-activated therapeutics and uses related thereto | 塔夫茨大学信托人 | 2022-01-21 | — | — | CN | disclosed |
| EP-0873123-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-10-28 | — | — | EP | disclosed |
| US-5783593-A | FUNGICIDE; ANTICHOLESTEROL AGENT | ABBOTT LABORATORIES (US) | 1998-07-21 | — | — | US | disclosed |
| EP-0821665-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1998-02-04 | — | — | EP | disclosed |
| WO-1997041824-A2 | ANTIANGIOGENIC PEPTIDES DERIVED FROM PLASMINOGEN | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0794789-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1997017070-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-05-15 | — | — | WO | disclosed |
| WO-1996034851-A1 | BENZENE, PYRIDINE, NAPHTALENE OR BENZOPHENONE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996034850-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-11-07 | — | — | WO | disclosed |
| WO-1996033159-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996021456-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1996-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266669-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SMN1; SMN2 3585/4885ALOX15 642/4885TSHR 4487/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SMN1; SMN2 3352/4885ALOX15 1035/4885TSHR 4245/4885 |
| US-20230303611-A1 | SYNTHESIS OF AN ANTIVIRAL AZASUGAR TRIPHOSPHATE | RNGTT, ADAR, MTAP | SMN1; SMN2 1719/4885ALOX15 3021/4885TSHR 3629/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | SMN1; SMN2 3600/4885ALOX15 653/4885TSHR 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.